Formularies and Higher Co-Pays Reduce Drug Outlays
Pharmaceutical Executive
Multi-tier formularies that set higher co-pays for the most expensive pharmaceuticals reduce beneficiaries' overall spending on prescriptions.
Multi-tier formularies that set higher co-pays for the most expensive pharmaceuticals reduce beneficiaries' overall spending on prescriptions. According to a study by Rand researchers, published in the October 9 issue of the Journal of the American Medical Association (JAMA), boosting cost sharing for brand-name medicines prompts consumers to switch to generic drugs and over-the-counter products or to stop using a medication altogether.
The analysis of claims data for more than 400,000 beneficiaries determined that plan members with $5 co-pays for all prescriptions spend an average of $725 annually on drugs, while members with $10 co-pays spend only $563 per year. Setting co-pays at $10 for generics and $20 for brand-name products brings member spending down to $455. However, adding a third tier with a $30 co-pay for non-preferred brand medicines lowered overall drug spending by only an additional 4 percent. Mandatory generic substitution had a larger impact, reducing drug spending by 8 percent.
Most of the savings went to health plans and employers-not beneficiaries. Patient advocates consequently claim that higher consumer co-pays force consumers to forego filling needed prescriptions. Researchers say they found no evidence of such an effect but acknowledge the need for further research on how drug benefit designs affect patients and prescription use.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
